Abstract 169P
Background
Pleural mesothelioma (PM) and non-small cell lung cancer (NSCLC) are aggressive thoracic malignancies with different cells of origin, pathogenesis and genetic features. Despite both tumors are treated with chemotherapy and immunotherapy, patients with PM and NSCLC exhibit varying responses. The aim of this study is to characterize the differences in tumor infiltrating immune cell populations in PM and NSCLC using high-dimensional flow cytometry analysis.
Methods
Fresh-frozen tumors derived from 42 PM and 30 NSCLC patients with available clinical data were analyzed. Single-cell suspensions were stained with a panel of 33 markers and samples were acquired using a Spectral Analyzer. An R-based pipeline for the in-depth characterization of the immune cells subsets was developed. Machine learning methods were used for unsupervised phenotypes discovery and differential abundant analysis was carried out to identify differences between samples. Correlation analysis with available clinical data was performed.
Results
By using high-dimensional single-cell analysis, 18 tissue-resident and invading immune cells subsets within the tumor immune microenvironment (TIME) of PM and NSCLC samples were identified. The comparison between the two tumor entities reveled significant differences in the tumor landscape, with increased infiltration of CD4+ and CD8+ T cell subsets in NSCLC compared to PM. While NSCLC tumors share similar tumor infiltrating immune cell subsets, PM tumors cluster in three distinct subgroups. Specifically, the subgroup with decreased infiltration of B cells and increased presence of tumor-associated macrophages is characterized by a significant worse overall survival (6 vs 18 vs 27 months, p=0.00012).
Conclusions
Our findings demonstrate significant differences in the composition of the TIME between PM and NSCLC, especially in T cell abundance. These disparities offer insights into the varying responses to immunotherapy. Moreover, we highlight the pivotal role of the TIME in predicting PM patient outcomes. These findings may be crucial to optimize immunotherapy for these malignancies, potentially leading to improve patients' outcomes.
Legal entity responsible for the study
The authors.
Funding
Stiftung für Angewandte Krebsforschung (SAKF).
Disclosure
I. Opitz: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca; Financial Interests, Personal, Advisory Board: AstraZeneca, MSD, BMS; Financial Interests, Personal, Other, Proctorship: Intuitive; Financial Interests, Institutional, Research Grant: Medtronic, Roche. A. Curioni-Fontecedro: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Novartis, Amgen, Roche, Takeda, Janssen; Non-Financial Interests, Personal, Leadership Role: Swiss Academy for Clinical Cancer Research (SAKK); Non-Financial Interests, Personal, Principal Investigator, of clinical trials: Roche; Non-Financial Interests, Personal, Principal Investigator, Clinical Trials: Takeda, MSD, Bristol Meyer Squibb, Amgen. All other authors have declared no conflicts of interest.
Resources from the same session
90P - HAIC plus sintilimab and bevacizumab biosimilar as treatment for patients with advanced hepatocellular carcinoma (HCC): a phase II trial
Presenter: HAIBIN ZHANG
Session: Poster Display
91P - A real-world study of tislelizumab (Anti-PD-1) plus tyrosine kinase inhibitors for intermediate or advanced hepatocellular carcinoma
Presenter: Wei zhang
Session: Poster Display
92P - TAE-HAIC plus lenvatinib and PD-1 inhibitors versus TAE-HAIC plus atezolizumab and bevacizumab for unresectable hepatocellular carcinoma: A propensity score matching study
Presenter: hongjie Cai
Session: Poster Display
93P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: a real-world, retrospective, multicentric study.
Presenter: Margherita Rimini
Session: Poster Display
94P - First-line chemotherapy plus immunotherapy versus chemotherapy alone for advanced gallbladder carcinoma
Presenter: Qin-qin Liu
Session: Poster Display
95P - A single-arm, multicenter phase ? trial evaluating TQB2450 plus anlotinib combined with paclitaxel and cisplatin in first-line treatment of advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Junsheng Wang
Session: Poster Display
97P - ICI for patients with MSS metastatic colorectal cancer
Presenter: Zayana Sangadzhieva
Session: Poster Display
Resources:
Abstract
99P - Efficacy and safety of toripalimab plus metronomic chemotherapy in HER2 negative metastatic breast cancer
Presenter: Hongnan Mo
Session: Poster Display